The deal will focus on heart patients who receive a cardiac resynchronization therapy device from Medtronic under a financial accountability program. The devices use an algorithm to regularly evaluate a patient’s heart rhythm and adjust therapy as needed. In clinical trials, the algorithm has been shown to reduce the risk of 30-day readmissions for heart failure and improve patient survival.
To assess the device’s real-world benefits for Spectrum patients, the two organizations will create a program to automatically identify readmissions among this patient population.
Spectrum said it plans to create and launch additional value-based healthcare programs with Medtronic to improve care and lower costs for patients in West Michigan.
To learn more, click here.
More articles on cardiology:
Az. Dignity hospital opens heart arrhythmia center
Heart associations update guidance on heart failure treatment
4 recent heart care partnerships
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
